Press Releases
Definiens to Present at First Rational Combinations 360° Conference in New York
MUNICH, GERMANY - Jun 20, 2016 - Definiens, the pioneer in Tissue Phenomics solutions for diagnostics development and commercialization, today announced that chief commercial officer Merrilyn Datta, PhD, will present at Rational Combinations 360°, being held in New York, NY from June 23-24, 2016. The event will bring together pharmaceutical and biotech companies seeking to accelerate clinical trials in the immuno-oncology space to discuss novel trial designs, and business and scientific developments for combination immunotherapies.
Dr. Dattas talk, entitled, Using Tissue-Based Assays to Stratify Patients in Clinical Trials, will present a case study illustrating the use of tissue biomarkers to understand which patients may respond to treatment in a mono immunotherapy trial. It will also include a discussion of the design for use in combination immuno-oncology therapies, and the importance of leveraging multiple genomic and tissue markers to predict clinical outcomes.
With image analysis technology, it is now possible to effectively stratify patients in clinical trials using tissue biomarkers, said Dr. Datta. Combination therapies will play a large role in the future of personalized cancer treatment, and the use of Tissue Phenomics, which includes correlating tissue data, genomics and clinical outcomes, is critical to predicting patient response and combination therapy decision-making in immuno-oncology.
Dr. Dattas presentation will take place on Friday, June 24, 2016 from 12:40 - 12:55 p.m. ET. For more information about the event, visit www.TheConferenceForum.org. For more information about Definiens technology, visit www.definiens.com.
About Definiens
Definiens is the pioneering provider of Tissue Phenomics® solutions for biomarker and companion diagnostics development and commercialization. Definiens technology empowers smarter tissue-based diagnostics by leveraging quantitative tissue readouts and other big data sources. By enabling the development of powerful and precise assays for patient stratification and clinical trial enrollment, Definiens aims to dramatically improve patient outcomes. Definiens' Tissue Phenomics approach was awarded the 2013 Frost and Sullivan Company of the Year Award for Global Tissue Diagnostics and Pathology Imaging. For more information, please visit: www.definiens.com.
Media contact:
Affect
Jonathan Moll, +1 212-398-9680
jmoll@affect.com
